PBYI vs TLRY · P/E 4.3, rev $56.5M vs rev $915.5M
Puma Biotechnology Inc (PBYI) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
PBYI currently screens at market cap $165.3M and trailing P/E 4.3. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the PBYI and TLRY stock pages for the full models.
Not investment advice.